Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-26
2009-02-10
Kaushal, Sumesh (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S003100, C530S300000, C530S303000, C530S308000, C530S324000
Reexamination Certificate
active
07488715
ABSTRACT:
The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
REFERENCES:
patent: 6232310 (2001-05-01), Hansen et al.
patent: 7041646 (2006-05-01), Pan et al.
patent: 9111457 (1991-08-01), None
Claus et al . J Endocrinol. 192(2):371-80, 2007.
Pan et al J Biol Chem. 281(18):12506-15, 2006.
Frezza et al, Dig Dis Sci. 52:643-649, 2007.
Combettes, Curr Opin Pharmacol. (6):598-605. 2006.
Bojanowska Med Sci Monit. 2005 (8):RA271-278, 2005.
Clairmont Kevin B.
Pan Clark
Whelan James
Bayer Pharmaceuticals Corporation
Edwards Angell Palmer & & Dodge LLP
Kaushal Sumesh
Kramer Barry
Loren Ralp A.
LandOfFree
Peptides acting as both GLP-1 receptor agonists and glucagon... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides acting as both GLP-1 receptor agonists and glucagon..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides acting as both GLP-1 receptor agonists and glucagon... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4130915